A Study of Reslizumab in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma

Summary

This is a multicenter, open-label (OL) extension study to obtain additional long-term safety data for subcutaneous (sc) administration of reslizumab treatment administered at a fixed dose of 110 mg in patients 12 years of age and older with severe eosinophilic asthma who completed the treatment period of a placebo-controlled Phase 3 trial of sc reslizumab. The study consists of a screening/baseline visit followed by a 36-week OL treatment period and a 15-week follow-up period.

Timeline

Start

2017-03-10

Primary completion

2018-02-22

Completion

2018-02-22

Drugs

Indications